Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: a survey among tertiary eye centers in Germany
Standard
Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: a survey among tertiary eye centers in Germany. / Jiang, Jana; Böhringer, Daniel; Auw-Hädrich, Claudia; Maier, Philip Christian; Barth, Teresa; Eter, Nicole; Fuest, Matthias; Geerling, Gerd; Heindl, Ludwig M; Herwig-Carl, Martina; Hintschich, Christoph; Hufendiek, Katerina; Kampik, Daniel; Lieb, Wolfgang; Meller, Daniel; Mueller, Arthur; Pfeiffer, Norbert; Rehak, Matus; Schargus, Marc; Seitz, Berthold; Spitzer, Martin; Stahl, Andreas; Süsskind, Daniela; van Oterendorp, Christian; Wagner, Felix Mathias; Westekemper, Henrike; Ziemssen, Focke; Reinhard, Thomas.
in: KLIN MONATSBL AUGENH, Jahrgang 240, Nr. 7, 07.2023, S. 891-896.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Current Practice in the Treatment of Epithelial and Melanocytic Tumours with Interferon-α2b: a survey among tertiary eye centers in Germany
AU - Jiang, Jana
AU - Böhringer, Daniel
AU - Auw-Hädrich, Claudia
AU - Maier, Philip Christian
AU - Barth, Teresa
AU - Eter, Nicole
AU - Fuest, Matthias
AU - Geerling, Gerd
AU - Heindl, Ludwig M
AU - Herwig-Carl, Martina
AU - Hintschich, Christoph
AU - Hufendiek, Katerina
AU - Kampik, Daniel
AU - Lieb, Wolfgang
AU - Meller, Daniel
AU - Mueller, Arthur
AU - Pfeiffer, Norbert
AU - Rehak, Matus
AU - Schargus, Marc
AU - Seitz, Berthold
AU - Spitzer, Martin
AU - Stahl, Andreas
AU - Süsskind, Daniela
AU - van Oterendorp, Christian
AU - Wagner, Felix Mathias
AU - Westekemper, Henrike
AU - Ziemssen, Focke
AU - Reinhard, Thomas
PY - 2023/7
Y1 - 2023/7
N2 - PURPOSE: To evaluate the standard of care, in particular the use of topical or subconjunctival interferon- α2b, in treating ocular surface squamous neoplasia or melanocytic tumours in tertiary eye centres in Germany. METHODS: A survey containing 14 questions was sent to 43 tertiary eye centres in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumours (primary acquired melanosis and malignant melanoma), as well as the clinical experiences and difficulties in prescribing off-label interferon- α2b eye drops and subconjunctival injections. RESULTS: Twenty-four tertiary eye centres responded to the survey. Eighty-three percent of centres had used interferon- α2b in their clinical practice and 25% prescribed it as the first-line cytostatic agent following surgical excision of ocular surface squamous neoplasia, while 10% would do so for melanocytic tumours. Correspondingly, the majority of respondents selected mitomycin C as their first-line agent. Side effects were uncommon with topical interferon- α2b eye drops but were more frequently reported after subconjunctival interferon- α2b injections. In total, eight centres had experience with interferon- α2b injections. The most significant obstacles perceived by ophthalmologists when prescribing interferon- α2b were its high cost and the reimbursement thereof. CONCLUSION: Off-label mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumours, with interferon- α2b being the standard second-line option. Interferon- α2b has predominantly been used to treat ocular surface squamous neoplasia and, to a lesser extent, melanocytic tumours at German tertiary eye centres. Following its market withdrawal, supply shortages of interferon- α2b are likely to have a profound impact on patient care and their quality of life.
AB - PURPOSE: To evaluate the standard of care, in particular the use of topical or subconjunctival interferon- α2b, in treating ocular surface squamous neoplasia or melanocytic tumours in tertiary eye centres in Germany. METHODS: A survey containing 14 questions was sent to 43 tertiary eye centres in Germany. The questions addressed the surgical and medical management of ocular surface squamous neoplasia and melanocytic tumours (primary acquired melanosis and malignant melanoma), as well as the clinical experiences and difficulties in prescribing off-label interferon- α2b eye drops and subconjunctival injections. RESULTS: Twenty-four tertiary eye centres responded to the survey. Eighty-three percent of centres had used interferon- α2b in their clinical practice and 25% prescribed it as the first-line cytostatic agent following surgical excision of ocular surface squamous neoplasia, while 10% would do so for melanocytic tumours. Correspondingly, the majority of respondents selected mitomycin C as their first-line agent. Side effects were uncommon with topical interferon- α2b eye drops but were more frequently reported after subconjunctival interferon- α2b injections. In total, eight centres had experience with interferon- α2b injections. The most significant obstacles perceived by ophthalmologists when prescribing interferon- α2b were its high cost and the reimbursement thereof. CONCLUSION: Off-label mitomycin C was the preferred adjuvant therapy for epithelial and melanocytic tumours, with interferon- α2b being the standard second-line option. Interferon- α2b has predominantly been used to treat ocular surface squamous neoplasia and, to a lesser extent, melanocytic tumours at German tertiary eye centres. Following its market withdrawal, supply shortages of interferon- α2b are likely to have a profound impact on patient care and their quality of life.
U2 - 10.1055/a-2029-0163
DO - 10.1055/a-2029-0163
M3 - SCORING: Journal article
C2 - 36746398
VL - 240
SP - 891
EP - 896
JO - KLIN MONATSBL AUGENH
JF - KLIN MONATSBL AUGENH
SN - 0023-2165
IS - 7
ER -
